Austausch von Inhalatoren in der Apotheke aufgrund des Rahmenvertrages vom 1. 4. 2008 und individueller Rabattverträge

Zusammenfassung

Die Verschreibung von Inhalativa durch den Arzt erfolgt nicht nur unter pharmakologischen Gesichtspunkten, sondern unter besonderer Berücksichtigung physikalischer Eigenschaften des Inhalationssystems, der speziellen und dosisrelevanten Galenik sowie der individuellen Krankheitssituation bzw. auch der intellektuellen und manuellen Fähigkeiten des Patienten. Die korrekte Handhabung der Systeme muss intensiv geschult und überprüft werden. Dies ist auch in den Disease Management Programmen (DMP) Asthma und COPD so verankert. Ein Austausch von Inhalationssystemen ohne Berücksichtigung der oben genannten Kriterien und ohne erneute Schulung widerspricht allen Empfehlungen nationaler und internationaler Fachgesellschaften und gefährdet die betroffenen Patienten.

Abstract

The prescription of an inhalative therapy by the physician is not only based on pharmacological aspects, but also on the physical characteristics of the inhalation device, the special and dose-relevant galenics as well as on the patient’s individual situation, e. g. disease severity, the intellectual and manual skills. The correct use of the various devices has to be trained and controlled. This approach is also fixed in the Disease Management Programmes (DMP) for asthma and COPD. The substitution of inhalation devices without consideration of the above-mentioned criteria and without retraining is contradictory to all recommendations of national and international respiratory societies and may put the patients at risk.

Literatur

• 1 Global Burden of Disease Study.  Lancet. 1997;  149 1263
• 2 Fabel H, Konietzko N. Weißbuch Lunge. Stuttgart: Thieme 2005
• 3 Dennis J H, Hendrick D J. Design characteristics for drug nebulizers.  J Med Eng Technol. 1992;  16 63-68
• 4 Newhouse M T. Aerosolerzeugung und Verteilungssysteme zur pulmonalen Medikamentenapplikation: Theorie und Praxis.  Innere Medizin. 1993;  48 363-368
• 5 Sakula A. A history of asthma.  J R Coll Physicians Lond. 1988;  22 36-44
• 6 Aerosol Consensus Statement.  Chest. 1991;  100 1106-1109
• 7 Morrow-Brown H, Storey G, George W HS. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma.  BMJ. 1972;  2 585-590
• 8 Visser J. Van der Waals and other cohesive forces affecting powder fluidization.  Powder Technol. 1989;  58 1-10
• 9 Webb J, Rees J, Clark T J. A comparison of the effects of different methods of administration of beta 2 sympathomimetics in patients with asthma.  Br J Dis Chest. 1982;  76 351-357
• 10 Boe J, Dennis J H. European respiratory society nebulizer guidelines: technical aspects.  Eur Respir Rev. 2000;  10 1-237 (Rev. 72)
• 11 British Thoracic Society, National Asthma Campaign, Royal College of Physicians of London . The British guidelines on asthma management: 1995 review and position statement.  Thorax. 1997;  52 S11
• 12 Byron P R. Pulmonary targeting with aerosols.  Pharm Technol. 1987;  5 42-54
• 13 Byron P R, Patton J S. Drug delivery via the respiratory tract.  J Aerosol Med. 1994;  7 49-75
• 14 Everard M L, Dolovich M. In vivo measurements of lung dose. In: Risgaard M, O'Callaghan C, Smaldone G (Hrsg). Drug delivery in the lung: clinical aspects. Lung biology in health and disease. New York: Marcel Dekker 2000
• 15 Heyder J. Deponierung von Aerosolteilchen im Atemtrakt des Menschen. In: Scheuch G. Aerosole in der Inhalationstherapie. München: Dustri 1997: 1-10
• 16 Köhler D, Fleischer W, Matthys H. Depositionsmuster von Dosieraerosolen im menschlichen Organismus.  Atemw Lungenkrkh. 1985;  11 340-341
• 17 Köhler D, Fleischer W. Theorie und Praxis der Inhalationstherapie. München: Arcis 2000
• 18 Smith K J, Chan H K, Brown K F. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers.  J Aerosol Med. 1998;  11 231-245
• 19 Dalby R N, Tiano S L, Hickey A J. Medical devices for the delivery of therapeutic aerosols to the lung. In: Hichey AJ (Hrsg). Inhalation Aerosols: Physical and Biological Basis for Therapy. New York: Marcel Dekker 1996: 441-474
• 20 Hickey A J, Evans R M. Aerosol generation from propellant-driven MDIs. In: Hichey AJ (Hrsg). Inhalation Aerosols: Physical and Biological Basis for Therapy. New York: Marcel Dekker 1996: 417-440
• 21 Ad Hoc Committee on Health Literacy for the Council of Scientific Affairs, American Medical Association, Health Literacy . Report of the Council of Scientific Affairs.  JAMA. 1999;  281 552-557
• 22 Armitage J M, Williams S J. Inhaler technique in the elderly.  Age and Ageing. 1988;  17 275-278
• 23 Crompton G. Problems patients have using pressurized aerosol inhalers.  Eur J Respir Dis. 1982;  63 101-104
• 24 Friegang B. New method of beclometasone aerosol administration to children under 4 years of age.  Can Med Assoc J. 1977;  117 1308-1309
• 25 Petro W, Gebert P, Lauber B. Ursachen fehlerhafter Anwendung von Dosieraerosolen.  Pneumologie. 1994;  48 191-196
• 26 Saunders K B. Misuse of inhaled bronchodilator agents.  BMJ. 1965;  1 1037-1038
• 27 Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability.  Eur Respir J. 2002;  19 246-251
• 28 Bronsky E A, Debelic M, Pujet J C. et al . Ease-of-use study of pirbuterol acetate in the Autohaler actuator in three countries: the United States, Germany, and France.  J Asthma. 1993;  30 439-443
• 29 Chapman K R, Love L, Brubaker H. A comparison of breath-actuated and conventional metered-dose inhaler inhalation techniques in elderly subjects.  Chest. 1993;  104 1332-1337
• 30 Fergusson R J, Lenney J, McHardy G JR. et al . The use of the Autohaler® device by patients with severe airflow obstruction.  Eur Resp J. 1991;  4 172-174
• 31 Goodman D E, Israel E, Rosenberg M. et al . The influence of age, diagnosis, and gender on proper use of metered-dose inhalers.  Am J Respir Crit Care Med. 1994;  150 1256-1261
• 32 Larsen J S, Hahn M, Ekholm B. et al . Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients.  J Asthma. 1994;  31 193-199
• 33 Marshik P L. A novel breath actuated device (Autohaler®) consistently actuates during the early phase of inspiration.  J Aerosol Med. 1995;  8 187-195
• 34 Newman S P, Weisz A WB, Talaee N. et al . Improvement of drug delivery with a breath actuated pressurized aerosol for patients with poor inhaler technique.  Thorax. 1991;  46 712-716
• 35 Brown P H, Ning A CWS, Greening A P. et al . Peak inspiratory flow through Turbohaler^® in acute asthma.  Eur Respir J. 1995;  8 1940-1941
• 36 Dewsbury N J, Kenyon C J, Newman S P. The effect of handling techniques on electrostatic charge on spacer devices: a correlation with in vivo particle size analysis.  Int J Parm. 1996;  137 216-264
• 37 Janssens H M, Devadason S G, Hop W CJ. Variability of aerosol delivery via spacer devices in young children in daily life.  Eur Respir J. 1999;  13 787-791
• 38 Newman S A, Morén F, Pavia D. et al . Deposition of pressurized suspension aerosols inhaled through extension devices.  Am Rev Respir Dis. 1991;  124 17-20
• 39 Newman S P, Millar A B, Lennard-Jones T R. et al . Improvement of pressurized aerosol deposition with the nebuhaler spacer device.  Thorax. 1984;  39 935-941
• 40 Barry P, O'Callaghan C. Poor output of salbutamol from a spacer device – the effect of spacer static charge and multiple actuations.  Thorax. 1994;  49 402
• 41 Barry P, O'Callaghan C. Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range.  Eur Respir J. 1994;  7 1707-1709
• 42 Bouchikhi A, Becquemin M H, Bignon J. et al . Particle size study of nine metered dose inhalers, and their deposition probabilities in the airways.  Eur Respir J. 1988;  1 547-552
• 43 Leach C L, Davidson P J, Boudreau R J. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone.  Eur Respir J. 1998;  12 1346-1353
• 44 Tansey I. The technical transition to CFC-free inhalers.  Br J Clin Pract Suppl. 1997;  89 22-27
• 45 Aubier M, Wettengel R, Gans S JM. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 µg/day) versus HFA-fluticasone propionate (1000 µg/day) in patients with asthma.  Respiratory Medicine. 2001;  95 212-220
• 46 Dahl R, Ringdal N, Ward S M. et al . Equivalence of asthma control with new CFC-free formulation HFA-134a beclomethasone dipropionate and CFC-beclomethasone dipropionate.  Br J Clin Pract. 1997;  51 11-15
• 47 Gross G, Thompson P J, Chervinsky P. et al . Hydrofluoroalkane-134a beclomethasone dipropionate, 400 µg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 µg, for the treatment of moderate asthma.  Chest. 1999;  115 343-351
• 48 Juniper E F, Buist A S. Health-related quality of life in moderate asthma: 400 µg hydrofluoroalkane beclomethasone dipropionate vs 800 µg chlorofluorocarbon beclomethasone dipropionate. The Study Group.  Chest. 1999;  116 1297-1303
• 49 Magnussen H. Equivalent asthma control after dose reduction with HFA-134a beclomethasone solution aerosol. Comparative Inhaled Steroid Investigation Group (CISIG).  Respir Med. 2000;  94 549-555
• 50 Worth H, Muir J F, Pieters W R. Comparison of hydrofluoroalkane-beclomethasone dipropionate Autohaler with budesonide Turbuhaler in asthma control.  Respiration. 2001;  68 517-526
• 51 Frieß S, Kutz G. Pulverinhalatoren: vom feindispersen System zum fertigen Arzneimittel.  Dtsch Apoth Ztg. 1993;  133 1242-1245
• 52 Hickey A J, Concessio N M, Oort M M van. et al . Factors influencing the dispersion of dry powders as aerosols.  Pharm Tech. 1994;  8 58-82
• 53 Brown P H, Blundell G, Greening A P. et al . Do large spacer devices reduce the systemic effects of high dose inhaled corticosteroids?.  Thorax. 1990;  45 736-739
• 54 Clark A R, Hollingworth A M. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy human volunteers – implications for in vitro testing.  J Aerosol Sci. 1993;  6 99-110
• 55 Hindle M, Byron P R. Dose emissions from marketed dry powder inhalers.  Int J Pharmaceut. 1995;  116 169-177
• 56 Newman S P, Hollingworth A, Clark A R. Effect of different modes of inhalation on drug delivery from a dry powder inhaler.  Int J Pharm. 1994;  102 127-132
• 57 Newman S P, Morén F, Trofast E. et al . Terbutaline sulphate turbohaler: effect of inhaled flow rate on drug deposition and efficacy.  Int J Pharm. 1991;  74 209-213
• 58 Ross D L, Schultz R K. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products.  J Aerosol Med. 1996;  9 215-226
• 59 Beerendonk I van, Mesters I, Mudde A N. et al . Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device.  J Asthma. 1998;  35 273-279
• 60 Voshaar T H, App E M, Berdel D. et al . Empfehlungen für die Auswahl von Inhalationssystemen zur Medikamentenverabreichung.  Pneumologie. 2001;  55 579-86